Can I Take Reishi Mushroom with Jardiance (Empagliflozin)?

What Is the Core Interaction Between Reishi and Jardiance?

Taking reishi mushroom alongside Jardiance introduces two overlapping pharmacodynamic effects that do not cancel each other out. Jardiance lowers blood glucose by blocking sodium-glucose cotransporter 2 (SGLT2) in the proximal tubule of the kidney, causing excess glucose to be excreted in urine. Reishi extracts contain bioactive polysaccharides and triterpenoids that appear to lower blood glucose through separate mechanisms, including alpha-glucosidase inhibition and possible enhancement of insulin sensitivity. When both agents act at the same time, blood glucose may drop further than either would cause alone.

A secondary concern involves reishi's antiplatelet and anticoagulant properties. Several in-vitro and animal studies show that Ganoderma polysaccharides reduce platelet aggregation and prolong bleeding time. Jardiance itself is not an anticoagulant, but many patients on Jardiance also carry diagnoses of heart failure or atherosclerotic cardiovascular disease and may be prescribed aspirin, warfarin, apixaban, or clopidogrel. Adding a supplement with antiplatelet activity to that combination raises the bleeding risk meaningfully.

Pharmacokinetic Considerations

Pharmacokinetic interactions between the two are considered low priority but not zero. Empagliflozin is primarily metabolized by UGT1A3, UGT1A8, UGT1A9, and UGT2B7, not by cytochrome P450 enzymes to any major degree. Reishi extracts have shown weak inhibition of CYP2C19 in cell-based assays, but empagliflozin's metabolism does not rely on CYP2C19 as a primary route, so the clinical relevance of this finding is uncertain. The more actionable concern remains the pharmacodynamic additive effect on glucose.

Pharmacodynamic Additive Effect on Glucose

A 2020 systematic review of 27 randomized controlled trials (total N = 2,589) assessed the hypoglycemic effects of G. Lucidum across multiple patient populations. The pooled analysis found that reishi supplementation was associated with a mean HbA1c reduction of 0.26% and a fasting plasma glucose reduction of 4.5 mg/dL compared with placebo, though the authors noted high heterogeneity (I² = 74%) across the included studies (1). These are modest reductions individually, but layered onto a drug like empagliflozin, which produces mean HbA1c reductions of approximately 0.7 to 0.8% at the 10 mg dose and 0.8 to 0.9% at the 25 mg dose in phase 3 trials, the combined glucose-lowering effect could push some patients into symptomatic hypoglycemia territory, particularly those with baseline HbA1c values already near target.

How Serious Is the Hypoglycemia Risk?

Jardiance by itself carries a relatively low intrinsic risk of hypoglycemia compared with insulin or sulfonylureas. SGLT2 inhibitors reduce glucose in a glucose-dependent fashion, and a landmark 2015 cardiovascular outcomes trial, EMPA-REG OUTCOME (N = 7,020), documented severe hypoglycemia rates of 1.5% in the empagliflozin group versus 1.5% in placebo over a median 3.1-year follow-up, confirming a neutral hypoglycemia profile for empagliflozin as monotherapy or on background metformin (2).

The risk calculus shifts when additional glucose-lowering agents are added. The American Diabetes Association 2024 Standards of Care note that combination glucose-lowering therapy increases hypoglycemia probability, and clinicians should review all medications and supplements at every encounter (3).

When Risk Is Elevated

Patients on triple or quadruple glucose-lowering regimens (for example, metformin plus empagliflozin plus a GLP-1 agonist, and then reishi on top) face a cumulative effect that none of the individual agents would trigger alone. Risk is also higher in patients over 70 years old, those with eGFR below 45 mL/min/1.73 m², and patients who skip meals or restrict carbohydrates significantly. For those individuals, the addition of even a modest glucose-lowering supplement like reishi may warrant more frequent glucose monitoring or a dose review by their prescriber.

Symptoms to Watch For

Classic hypoglycemia symptoms include shakiness, diaphoresis, palpitations, and confusion. Patients on empagliflozin should be advised that urinary glucose loss can also cause dehydration-related dizziness that mimics early hypoglycemia. Distinguishing between the two requires a fingerstick glucose measurement. A value below 70 mg/dL (3.9 mmol/L) confirms hypoglycemia per ADA criteria (3).

Does Reishi Mushroom Affect Bleeding Risk in Jardiance Users?

Jardiance does not directly affect coagulation or platelet function, but the population prescribed it frequently overlaps with people who take anticoagulants or dual antiplatelet therapy. A prospective cohort from EMPA-REG OUTCOME enrolled patients with established cardiovascular disease, where antiplatelet use was common. Adding reishi to that clinical picture introduces an independent platelet-inhibitory signal.

Mechanism of Reishi's Antiplatelet Effect

Ganoderma triterpenoids, specifically ganoderic acids B, D, F, H, K, and S, have been shown to inhibit platelet aggregation induced by collagen and ADP in human platelet-rich plasma preparations. A 2011 in-vitro study isolated these triterpenes and quantified inhibition rates ranging from 22% to 49% of collagen-induced aggregation at concentrations of 100 micrograms per mL (4). These are cell-culture concentrations, and translating them to oral supplement doses requires caution, but the mechanism is biologically plausible.

Who Faces the Greatest Bleeding Concern

Patients who combine Jardiance with warfarin (target INR 2.0 to 3.0), apixaban 5 mg twice daily, rivaroxaban 20 mg daily, or dual antiplatelet therapy (aspirin plus clopidogrel) should treat any supplement with antiplatelet activity as additive to their existing bleeding risk. The prescriber managing anticoagulation should be informed before reishi is started or stopped, because stopping an antiplatelet-active supplement can also shift the anticoagulation balance unexpectedly.

What Does the Evidence on Reishi and Diabetes Show?

The clinical evidence for reishi as a glucose-lowering agent in humans is genuinely mixed, and it is important to read the trials rather than the supplement marketing copy. The 2020 Cochrane-methodology systematic review cited above (1) found that while pooled data favored reishi over placebo, the included trials were small (median N = 54 per trial), used heterogeneous preparations (dried powder, hot-water extract, spore oil), and reported follow-up periods ranging from 4 weeks to 6 months. None of the trials used empagliflozin as background therapy.

A 2003 randomized controlled trial by Gao et al. (N = 71) published in the Journal of Medicinal Food tested a G. Lucidum polysaccharide extract (1,800 mg/day for 12 weeks) in patients with type 2 diabetes on diet alone or oral agents. Fasting glucose fell by a mean 11.0 mg/dL in the reishi group versus 3.5 mg/dL in placebo (P<0.05). HbA1c improved by 0.4% in the reishi arm (5). Subjects in that trial were on modest background therapy, not SGLT2 inhibitors, which did not exist at the time.

What Reishi Preparations Are Commercially Available?

Reishi is sold as whole dried mushroom powder, hot-water-extracted polysaccharide concentrate, ethanol-extracted triterpene concentrate, and dual-extraction blends that aim to capture both polysaccharide and triterpene fractions. The glucose-lowering data comes predominantly from hot-water polysaccharide extracts standardized to beta-glucan content (typically 10 to 30%). Triterpene-standardized ethanol extracts are the fraction most associated with platelet inhibition. A dual-extract product will carry both activities simultaneously, which matters for the interaction assessment.

Dose Ranges Used in Trials

Trials have used doses ranging from 900 mg to 5,400 mg of dried extract equivalent per day. The most commonly studied clinical dose is 1,800 mg/day of a polysaccharide extract, which is also the dose range of many commercial products. Higher doses may produce more pronounced glucose effects but are also more likely to exert measurable antiplatelet activity.

Is Reishi Mushroom Metabolized the Same Way as Empagliflozin?

No. These two compounds travel entirely different metabolic paths. Empagliflozin undergoes glucuronidation via hepatic and intestinal UGT enzymes and is excreted primarily in feces (41%) and urine (54%), with a half-life of approximately 12.4 hours following a 25 mg oral dose (6). Reishi polysaccharides are not absorbed intact; they are partially fermented in the colon and their bioactive fractions enter systemic circulation as smaller oligosaccharides. Reishi triterpenoids are absorbed via passive diffusion and undergo hepatic first-pass metabolism, with measurable plasma concentrations appearing within 1 to 2 hours of an oral dose.

Because their primary metabolic routes do not heavily overlap, a pharmacokinetic drug-drug interaction in the classic sense (one compound slowing the clearance of the other) is unlikely to be clinically significant at standard doses. The concern is the pharmacodynamic signal, not the metabolic one.

What Do Current Guidelines Say About Herbal Supplements and SGLT2 Inhibitors?

No current FDA prescribing guidance, ADA Standards of Care, or ACC/AHA heart failure guidelines specifically address reishi mushroom co-administration with empagliflozin by name. The FDA label for Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) does not list botanical supplements in its drug-interaction section, which reflects the absence of formal pharmacokinetic studies rather than confirmed safety (6).

The 2024 ADA Standards of Care, Section 9 (Pharmacologic Approaches to Glycemic Treatment), state: "Clinicians should ask about the use of complementary and alternative medicines, including dietary supplements, at every visit, because these agents may have additive or antagonistic effects on glycemic control and cardiovascular risk factors" (3).

The Natural Medicines database rates the interaction between G. Lucidum and antidiabetic drugs as "moderate" and flags the combination as warranting monitoring. The Mayo Clinic Proceedings supplement interaction framework similarly categorizes reishi as having potential additive hypoglycemic effects with glucose-lowering medications.

What Pharmacists Typically Advise

Most clinical pharmacists reviewing this combination apply a standard additive-effect assessment. Because Jardiance alone carries low intrinsic hypoglycemia risk, a well-controlled patient on empagliflozin monotherapy with HbA1c between 7.0 and 8.0% who wants to take a standard commercial reishi extract (1,800 mg/day) may be a reasonable candidate with appropriate monitoring rather than an outright refusal. The risk tier rises considerably if insulin, sulfonylurea, or meglitinide therapy is also present in the regimen.

Practical Monitoring Protocol If You Are Already Taking Both

If you are already combining reishi with Jardiance, or your prescriber decides the combination is acceptable for your situation, the following monitoring steps reduce the risk of undetected harm.

Glucose Monitoring

Check fasting glucose at home for the first 2 weeks after adding reishi. Log the values and flag any reading below 70 mg/dL. If you wear a continuous glucose monitor (CGM), review time-in-range statistics weekly. A drop in average glucose of more than 15 to 20 mg/dL from your pre-reishi baseline suggests the supplement is producing a meaningful pharmacodynamic effect and your prescriber should review your regimen.

Bleeding Awareness

Look for unexplained bruising, prolonged bleeding from minor cuts, or blood in urine or stool. These signs do not necessarily indicate a crisis, but they should prompt a same-day call to your care team rather than a wait-and-see approach. If you also take warfarin, schedule an INR check within 2 to 3 weeks of starting reishi, because even a modest shift in platelet function can alter the apparent anticoagulation balance.

HbA1c Review

Request an HbA1c at the next scheduled lab draw (usually every 3 months). Compare to the pre-reishi baseline. An unexpected drop of more than 0.5% warrants a medication review appointment rather than simply celebrating the improvement, because it may signal that your current empagliflozin dose plus the supplement is producing more glucose lowering than planned.

When to Stop Immediately

Stop reishi and contact your prescriber the same day if you experience symptomatic hypoglycemia (confirmed by fingerstick below 70 mg/dL), an unexplained bleeding episode, signs of urinary tract infection (Jardiance already mildly elevates UTI risk), or any allergic reaction such as hives or angioedema. Reishi has been associated with rare but documented hepatotoxicity in case reports, and any new elevation in liver enzymes (ALT more than 3 times the upper limit of normal) should be reported immediately (7).

How to Talk to Your Prescriber About This Combination

Many patients feel awkward mentioning supplements to their physician or diabetes care team. A direct approach works best. Tell your prescriber: "I am interested in taking a reishi mushroom extract, approximately 1,800 mg per day. I understand it may lower blood sugar and affect platelets. Can you review my current regimen and tell me whether monitoring is sufficient, or whether this is inadvisable given my specific situation?"

That specific framing helps your clinician move past generic "avoid all supplements" advice and into a personalized risk-benefit analysis. Bring the product label so the standardization (percent beta-glucan, percent triterpenoids) and the extraction method are visible. A dual-extract product carries more combined activity than a plain hot-water extract.

If your prescriber is unfamiliar with the reishi literature, referring them to the 2020 systematic review in the Journal of Ethnopharmacology (PMID 32213076) or the Natural Medicines interaction monograph gives them a starting point for a 5-minute review.

Key Takeaways for Patients and Clinicians

Reishi mushroom is not a high-risk supplement in most otherwise-healthy adults, but "generally regarded as safe" does not mean "safe to add freely to a diabetes medication regimen." The combination of Jardiance and reishi creates at least two pharmacodynamic interactions, both of which are manageable with proper oversight but neither of which should be assumed trivial.

The additive glucose-lowering effect is the primary concern. Patients on empagliflozin monotherapy with good baseline control face modest incremental risk. Patients on multi-drug regimens with baseline HbA1c already at or near target face meaningfully higher hypoglycemia exposure. The antiplatelet effect matters most when anticoagulants or antiplatelet drugs are already part of the regimen.

Neither the FDA nor the ADA has issued a formal contraindication. The appropriate response is informed, monitored co-use or a deliberate decision not to combine the two, based on the individual patient's full medication list, renal function, cardiovascular status, and glycemic control targets.

Patients currently on empagliflozin 10 mg or 25 mg once daily who are considering any reishi supplement should measure fasting glucose at home for two consecutive weeks immediately after starting and schedule a HbA1c check within 90 days to objectively assess whether the combination is shifting their glycemic control beyond their individualized target range.